CG Oncology Secures $1.1B Cash, Extends Runway to 2029, Targets Q4 BLA Filing
Summary
CG Oncology reported a significantly strengthened cash position of $1.1 billion as of March 31, 2026, including $391.4 million from at-the-market (ATM) sales in Q1. This robust cash balance is projected to fund operations through 2029, substantially de-risking the company's financial outlook. The company also confirmed it is on track to finalize its Biologics License Application (BLA) submission in the fourth quarter of 2026, following successful completion of non-clinical and clinical modules. Additionally, CG Oncology anticipates key clinical data readouts in the coming months, including topline data from the Phase 3 PIVOT-006 trial and first results from the Phase 2 CORE-008 Cohort CX. The appointment of Jim DeTore as Chief Financial Officer further strengthens the executive leadership team.
At the time of this announcement, CGON was trading at $69.10 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $5.8B. The 52-week trading range was $21.00 to $73.56. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.